Lv4
500 积分 2021-04-08 加入
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1个月前
已完结
Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)
1个月前
已完结
[Development in the last 20 years of anti-HER2 targeted therapy for breast cancer]
2个月前
已完结
Oral vinorelbine in the treatment of non-small-cell lung cancer
4个月前
已完结
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
4个月前
已完结
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC ‡ 04-2017)
4个月前
已完结
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC ‡ 04-2017)
4个月前
已关闭
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
5个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
5个月前
已完结
皖公网安备34019202002308
